Higher risk of Parkinson disease in patients with primary Sjögren’s syndrome
- 2 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 39 (10), 2999-3007
- https://doi.org/10.1007/s10067-020-05053-z
Abstract
This study assessed the risk of Parkinson disease (PD) in patients with primary Sjögren’s syndrome (pSS) using a nationwide, population-based cohort during a 15-year follow-up period.This publication has 18 references indexed in Scilit:
- Parkinson diseaseNature Reviews Disease Primers, 2017
- Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS CohortRMD Open, 2016
- Neuroinflammation in Parkinson’s disease and its potential as therapeutic targetTranslational Neurodegeneration, 2015
- Insights into Neuroinflammation in Parkinson’s Disease: From Biomarkers to Anti-Inflammatory Based TherapiesBioMed Research International, 2015
- Neuroinflammation in Parkinson’s Disease Animal Models: A Cell Stress Response or a Step in Neurodegeneration?Current Topics in Behavioral Neurosciences, 2014
- Inhibition of Neuroinflammation and Mitochondrial Dysfunctions by Carbenoxolone in the Rotenone Model of Parkinson’s DiseaseMolecular Neurobiology, 2014
- Parkinsonism: An under-recognized neurological complication of Sjogren's syndromeJournal of the Neurological Sciences, 2013
- Anti-inflammatory drugs and risk of Parkinson diseaseNeurology, 2010
- Neuroinflammation in Parkinson's disease: a target for neuroprotection?The Lancet Neurology, 2009
- Hemiparkinsonism in a patient with primary Sjögren's syndromeClinical Neurology and Neurosurgery, 1993